ClinicalTrials.gg
RecruitingNCT04389632Updated Jul 6, 2026

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

A Phase 1 interventional study of sigvotatug vedotin and pembrolizumab in Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck and HER2 Negative Breast Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Recruiting at 158 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1,006
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.

Planned enrollment
3rd of 136
1,006 · median 79
Started
2020
with 13 others
Phase 1
56 of 158
6 open now
Primary completion
2027-06
later than 7 of 25 live
Registered
98th of 158
by date

Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 3rd largest by planned enrollment of the 136 interventional ones that give a count, is one of 14 that started in 2020, is one of 56 in phase 1, reaches primary completion later than 7 of the 25 other live ones, and was the 98th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, or all of them as a file.
02

Study summary

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors.

The study will have four parts.

  • Part A of the study will find out how much sigvotatug vedotin should be given to participants.
  • Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors.
  • Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs.
  • Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors.
  • In Parts C and D, participants will receive sigvotatug vedotin with either:

    • Pembrolizumab or,
    • Pembrolizumab and carboplatin, or
    • Pembrolizumab and cisplatin.
03

Conditions studied

  • Carcinoma, Non-Small Cell Lung
  • Squamous Cell Carcinoma of Head and Neck
  • HER2 Negative Breast Neoplasms
  • Esophageal Squamous Cell Carcinoma
  • Esophageal Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Ovarian Neoplasms
  • Cutaneous Squamous Cell Cancer
  • Exocrine Pancreatic Adenocarcinoma
  • Urinary Bladder Neoplasms
  • Uterine Cervical Neoplasms
  • Stomach Neoplasms

Keywords

  • NSCLC
  • HNSCC
  • cSCC
  • ESCC
  • EAC
  • GEJ
  • HGSOC
  • Advanced HER2-Negative Breast Cancer
  • High Grade Serous Ovarian Cancer
  • Non-Small Cell Lung Cancer
  • Head and Neck Squamous Cell Cancer
  • Esophageal Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Gastric Cancer
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Disease indication

    • Participants must have or cytologically confirmed or unresectable solid within one of the tumor types listed below (dependent on study part).

      • Non-small cell lung cancer (NSCLC)
      • Head and neck squamous cell cancer (HNSCC)
      • Advanced -negative breast cancer
      • Esophageal squamous cell carcinoma (ESCC)
      • Esophageal/Gastro-esophageal junction adenocarcinoma (EAC/GEJ)
      • Cutaneous squamous cell cancer (cSCC)
      • Exocrine pancreatic adenocarcinoma
      • Bladder cancer
      • Cervical cancer
      • Gastric cancer
      • High grade serous ovarian cancer (HGSOC)
    • Part A only: Participants must have disease that is or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic options.
    • Part B only: Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies. Participants must have received platinum-based therapy and a /PD-(L)1 inhibitor, if applicable and available.
    • Part C only: For pembrolizumab combination cohorts, participants must be eligible for pembrolizumab per local standard of care. For pembrolizumab with cisplatin or carboplatin, participants must be eligible for both pembrolizumab and the platinum agent per local standard of care. Participants must be treatment naïve for locally advanced or metastatic systemic therapy (prior definitively intended or [neo] therapy is allowed).
    • Part D only: Participants must be treatment naïve for locally advanced or metastatic systemic therapy.
  • Participants enrolled in the following study parts should have a tumor site accessible for and agree to biopsy as follows:

    • Disease-specific expansion cohorts (Part B and Part D): A baseline fresh tumor biopsy is required. An archival biopsy collected within 90 days prior to first dose of study drug may be used.
    • Biology expansion cohort: pretreatment biopsy and on-treatment (Cycle 1) biopsy
  • An (ECOG) Performance Status of 0 or 1
  • per the v1.1 at baseline

Exclusion criteria

Exclusion Criteria

  • History of another within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of or death.
  • Known active central nervous system metastases. Participants with previously treated may participate provided they:

    • are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment,
    • have no new or enlarging brain metastases, and
    • are off of prescribed for symptoms associated with brain metastases for at least 7 days prior to first dose of study drug.
    • In Part D, participants with untreated, asymptomatic CNS metastases smaller than 1 cm may be enrolled without definitive treatment as long as they have no neurological symptoms, no or minimal surrounding edema, and no requirements for corticosteroids.
  • Carcinomatous meningitis
  • Previous receipt of an MMAE-containing agent or an agent targeting integrin beta-6
  • Pre-existing neuropathy Grade 1 or greater per the National Cancer Institute's , version 5.0 (NCI CTCAE v5.0) for Parts C and D cohorts with cisplatin or carboplatin; Grade 2 or greater per the NCI CTCAE v5.0 for all other cohorts
  • Any uncontrolled Grade 3 or higher (per NCI CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of sigvotatug vedotin.

    • Routine antimicrobial prophylaxis is permitted
  • Grade ≥3 pulmonary disease unrelated to underlying malignancy. This includes clinically severe pulmonary function compromise resulting from pulmonary illnesses
  • Part C and D: Prior therapy with a inhibitor, anti-PD-(L)1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a Grade 3 or higher immune-mediated adverse event (IMAE).
  • History of noninfectious interstitial lung disease (ILD) or pneumonitis that required steroids, current ILD or pneumonitis, or suspected ILD or pneumonitis that cannot be ruled out by imaging at screening
  • Known diffusing capacity of the lung for carbon monoxide (DLCO; adjusted for ) \<50% predicted
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,006 participants (estimated)

Study arms

  • Experimental
    Part A: Dose escalation

    sigvotatug vedotin monotherapy

    Drug: sigvotatug vedotin

  • Experimental
    Part B: Dose expansion

    sigvotatug vedotin monotherapy

    Drug: sigvotatug vedotin

  • Experimental
    Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCC

    sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)

    Drug: sigvotatug vedotin · Drug: pembrolizumab · Drug: cisplatin · Drug: carboplatin

  • Experimental
    Part D: sigvotatug vedotin combination therapy in 1L NSCLC

    sigvotatug vedotin + pembrolizumab +/- (carboplatin)

    Drug: sigvotatug vedotin · Drug: pembrolizumab · Drug: carboplatin

  • Experimental
    Part D: sigvotatug vedotin combination therapy in 1L HNSCC

    sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)

    Drug: sigvotatug vedotin · Drug: pembrolizumab · Drug: cisplatin · Drug: carboplatin

Interventions

  • Administered into the vein (IV; intravenously)

    Also known as: SGN-B6A, PF-08046047

  • 200mg every 3 weeks or 400mg every 6 weeks, given by IV

    Also known as: Keytruda

  • 75 mg/m2 every 3 weeks, given by IV

  • AUC 5 mg/mL per min every 3 weeks, given by IV

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Through 30-37 days following last dose of sigvotatug vedotin. For participants receiving pembrolizumab up to 90 days after last dose of pembrolizumab; up to 3 years

  2. Number of patients with laboratory abnormalities

    Time frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

  3. Number of participants with dose-limiting toxicities (DLTs)

    Time frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

Secondary outcomes

  1. Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator assessment

    The proportion of participants with complete response (CR) or partial response (PR) which is subsequently confirmed as assessed according to RECIST v1.1.

    Time frame: Up to approximately 3 years

  2. Duration of objective response (DOR) per RECIST v1.1 by investigator assessment

    The time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD) or to death due to any cause

    Time frame: Up to approximately 3 years

  3. Progression-free survival (PFS) per RECIST v1.1 by investigator assessment

    The time from the start of any study treatment to the first documentation of PD, or death due to any cause

    Time frame: Up to approximately 3 years

  4. Overall survival (OS)

    The time from the start of any study treatment to the date of death due to any cause

    Time frame: Up to approximately 3 years

  5. Area under the concentration-time curve (AUC)

    Pharmacokinetic (PK) endpoint

    Time frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

  6. Concentration at the end of infusion (Ceoi)

    PK endpoint

    Time frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

  7. Maximum observed concentration (Cmax)

    PK endpoint

    Time frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

  8. Time to maximum observed concentration (Tmax)

    PK endpoint

    Time frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

  9. Trough concentration (Ctrough)

    PK endpoint

    Time frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

  10. Apparent terminal elimination half-life (t1/2)

    PK endpoint

    Time frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

  11. Number of participants with antidrug antibodies (ADAs)

    Time frame: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

07

Study locations

145 of 158 sites recruiting
  • Alaska Oncology and Hematology
    Anchorage, Alaska 99508, United States
    Recruiting
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
    Recruiting
  • Highlands Oncology Group
    Rogers, Arkansas 72758, United States
    Recruiting
  • Highlands Oncology Group
    Springdale, Arkansas 72762, United States
    Recruiting
  • Providence Medical Foundation
    Anaheim, California 92805, United States
    Recruiting
  • Providence Medical Foundation
    Fullerton, California 92835, United States
    Recruiting
  • Providence St. Jude Medical Center Virginia K Crosson and Infusion Center
    Fullerton, California 92835, United States
    Recruiting
  • Cancer and Blood Research Center, LLC
    Los Alamitos, California 90720, United States
    Not yet recruiting
  • Cancer and Blood Specialty Clinic
    Los Alamitos, California 90720, United States
    Not yet recruiting
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
    Recruiting
  • The Regents of the University of California
    Los Angeles, California 90095, United States
    Recruiting
  • UCLA Department of Medicine-Hematology/Oncology
    Los Angeles, California 90095, United States
    Recruiting
  • UCLA Department of Medicine - Hematology & Oncology
    Santa Monica, California 90404, United States
    Recruiting
  • Cancer AND Blood Specialty Clinic
    Torrance, California 90505, United States
    Not yet recruiting
  • American Oncology Partners, PA. a Florida professional service corporation, d/b/a Vista Oncology
    Fort Myers, Florida 33913, United States
    Recruiting
  • Florida Cancer Specialists & Research Institute, LLC
    Fort Myers, Florida 33916, United States
    Recruiting
  • Memorial Cancer Institute
    Hollywood, Florida 33021, United States
    Recruiting
  • Memorial Healthcare System
    Hollywood, Florida 33021, United States
    Recruiting
  • Florida Cancer Specialists
    Orlando, Florida 32827, United States
    Recruiting
  • Memorial Cancer Institute at Memorial Hospital West
    Pembroke Pines, Florida 33028, United States
    Recruiting
  • Memorial Hospital West
    Pembroke Pines, Florida 33028, United States
    Recruiting
  • Ingalls Family Care Center
    Calumet City, Illinois 60409, United States
    Recruiting
  • UChicago Medicine - River East
    Chicago, Illinois 60611, United States
    Recruiting
  • The University Of Chicago
    Chicago, Illinois 60637, United States
    Recruiting
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
  • UChicago Medicine at Ingalls - Flossmoor
    Flossmoor, Illinois 60422, United States
    Recruiting
  • UChicago Medicine Ingalls Memorial
    Harvey, Illinois 60426, United States
    Recruiting
  • University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
    New Lenox, Illinois 60451, United States
    Recruiting
  • The University of Chicago Medicine Center for Advanced Care Orland Park
    Orland Park, Illinois 60462, United States
    Recruiting
  • Southern Illinois University - Simmons Cancer Institute
    Springfield, Illinois 62702, United States
    Recruiting
  • Springfield Clinic Radiology - 800 Building
    Springfield, Illinois 62702, United States
    Recruiting
  • Springfield Clinic Urgent Care Plus
    Springfield, Illinois 62702, United States
    Recruiting
  • Springfield Clinic
    Springfield, Illinois 62702, United States
    Recruiting
  • Springfield Clinic Main Campus
    Springfield, Illinois 62703, United States
    Recruiting
  • Springfield Clinic Radiology - Main Campus
    Springfield, Illinois 62703, United States
    Recruiting
  • Springfield Memorial Hospital
    Springfield, Illinois 62781, United States
    Recruiting
  • UChicago Medicine at Ingalls - Tinley Park
    Tinley Park, Illinois 60477, United States
    Recruiting
  • UChicago Medicine - Northwest Indiana
    Crown Point, Indiana 46307, United States
    Recruiting
  • Fort Wayne Medical Oncology and Hematology, Inc
    Fort Wayne, Indiana 46804, United States
    Recruiting
  • Community Health Network, Inc
    Indianapolis, Indiana 46219, United States
    Recruiting
  • Community Health Network, Inc.
    Indianapolis, Indiana 46227, United States
    Recruiting
  • Community Health Network Investigational Drug Services
    Indianapolis, Indiana 46250, United States
    Recruiting
  • Community Health Network, Inc.
    Indianapolis, Indiana 46250, United States
    Recruiting
  • The University of Kansas Cancer Center, Investigational Drug Services
    Fairway, Kansas 66205, United States
    Recruiting
  • The University of Kansas Clinical Research Center
    Fairway, Kansas 66205, United States
    Recruiting
  • The University of Kansas Hospital
    Kansas City, Kansas 66160, United States
    Recruiting
  • The University of Kansas Medical Center Medical Office Building
    Kansas City, Kansas 66160, United States
    Recruiting
  • University of Kansas Hospital Cambridge North Tower A
    Kansas City, Kansas 66160, United States
    Recruiting
  • University of Kansas Medical Center Research Institute
    Kansas City, Kansas 66160, United States
    Recruiting
  • The University of Kansas Cancer Center - Indian Creek Campus
    Overland Park, Kansas 66211, United States
    Recruiting
  • The University of Kansas Cancer Center - Westwood
    Westwood, Kansas 66205, United States
    Recruiting
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
  • Beth Israel Deaconess Medical Center,East Campus Research Pharmacy
    Boston, Massachusetts 02215, United States
    Recruiting
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
  • Dana-Farber Cancer Institute - Chestnut Hill
    Newton, Massachusetts 02467, United States
    Recruiting
  • Allina Health Cancer Institute - Mercy Hospital
    Coon Rapids, Minnesota 55433, United States
    Recruiting
  • Allina Health Cancer Institute - Abbott Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
    Recruiting
  • Allina Health Cancer Institute - United Hospital
    Saint Paul, Minnesota 55102, United States
    Recruiting
  • Allina Health Cancer Institute
    Saint Paul, Minnesota 55102, United States
    Recruiting
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
    Recruiting
  • North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists
    Babylon, New York 11702, United States
    Recruiting
  • North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists
    Brooklyn, New York 11210, United States
    Recruiting
  • North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists
    New Hyde Park, New York 11042, United States
    Recruiting
  • North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists
    New York, New York 10028, United States
    Recruiting
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
    Recruiting
  • North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists
    Patchogue, New York 11772, United States
    Recruiting
  • North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists
    Port Jefferson Station, New York 11776, United States
    Recruiting
  • North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists
    Riverhead, New York 11901, United States
    Recruiting
  • North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists
    Shirley, New York 11967, United States
    Recruiting
  • North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists
    The Bronx, New York 10469, United States
    Recruiting
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • OU Health University of Oklahoma Medical Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • Stephenson Cancer Center (chemo location)
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • University of Oklahoma Health Science Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • Providence Cancer Institute Franz Clinic
    Portland, Oregon 97213, United States
    Recruiting
  • Providence Oncology and Hematology Care Clinic - Westside
    Portland, Oregon 97225, United States
    Recruiting
  • Providence St. Vincent Medical Center- Investigational Drug Services
    Portland, Oregon 97225, United States
    Recruiting
  • Providence St. Vincent Medical Center
    Portland, Oregon 97225, United States
    Recruiting
  • Sanford Cancer Center
    Sioux Falls, South Dakota 57104, United States
    Recruiting
  • Sanford USD Medical Center
    Sioux Falls, South Dakota 57105, United States
    Recruiting
  • US Oncology Research LLC
    Nashville, Tennessee 37203, United States
    Recruiting
  • Oncology Consultants, PA
    Houston, Texas 77024, United States
    Recruiting
  • Oncology Consultants, PA.
    Houston, Texas 77030, United States
    Recruiting
  • The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
  • US Oncology Investigational Product Center (IPC)
    Irving, Texas 75063, United States
    Recruiting
  • Houston Medical Imaging
    Pearland, Texas 77581, United States
    Not yet recruiting
  • South Texas Accelerated Research Therapeutics, LLC
    San Antonio, Texas 78229, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UT Health East Texas HOPE Cancer Center
    Tyler, Texas 75701, United States
    Recruiting
  • UT Health East Texas Hope Cancer Center
    Tyler, Texas 75708, United States
    Recruiting
  • Tranquil Clinical Research
    Webster, Texas 77598, United States
    Not yet recruiting
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
    Recruiting
  • Northwest Medical Specialities. PLLC
    Bonney Lake, Washington 98391, United States
    Not yet recruiting
  • Swedish Cancer Institute - Edmonds Campus
    Edmonds, Washington 98026, United States
    Recruiting
  • Swedish Cancer Institute Edmonds Campus
    Edmonds, Washington 98026, United States
    Recruiting
  • Northwest Medical Specialities.PLLC
    Federal Way, Washington 98003, United States
    Not yet recruiting
  • Northwest Medical Specialities. PLLC
    Gig Harbor, Washington 98332, United States
    Not yet recruiting
  • American Oncology Network Vista Oncology Division-West office
    Olympia, Washington 98502, United States
    Recruiting

Showing the first 100 of 158 sites across 7 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Lyon RP, Jonas M, Frantz C, Trueblood ES, Yumul R, Westendorf L, Hale CJ, Stilwell JL, Yeddula N, Snead KM, Kumar V, Patilea-Vrana GI, Klussman K, Ryan MC. SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Mol Cancer Ther. 2023 Dec 1;22(12):1444-1453. doi: 10.1158/1535-7163.MCT-22-0817. PubMed 37619980 ↗

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jun 2027, 84 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 84 months is above that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2020
First posted
May 15, 2020
StartActual
Jun 8, 2020
Primary completionEst.
Jun 16, 2027
CompletionEst.
Mar 22, 2029
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04389632
Responsible party
Sponsor
First posted
May 15, 2020
Start date
Jun 8, 2020
Primary completion
Jun 16, 2027 (estimated)
Completion
Mar 22, 2029 (estimated)
Last update
Jul 6, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sigvotatug vedotin

Start the discussion